Literature DB >> 7554405

Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA).

D J Wheeler1, A Robins, D I Pritchard, R V Bundick, F Shakib.   

Abstract

In this study, we investigated the modulatory effects of CsA on in vitro synthesis of IgE, IgG1 and IgG4 by human peripheral blood mononuclear cells (PBMC). In contrast to its known immunosuppressive effect, we have demonstrated that a low dose of CsA (10(-7) M, 120 ng/ml) potentiated IgE production by up to 40-fold (i.e. from 33 +/- 4.5 to 1346 +/- 290 ng/ml). This potentiation was specific for IgE since no such effect was demonstrable with IgG1 and IgG4. Potentiation of IgE synthesis by CsA in the PBMC cultures was partly due to CsA acting on T cells, as demonstrated by the addition of CsA-treated T cells to T cell-depleted cultures. However, potentiation was also demonstrable in a T cell-depleted, anti-CD40-stimulated culture (four-fold increase from 400 +/- 48 to 1606 +/- 127 ng/ml). Our data therefore suggest that there are at least two mechanisms for CsA-induced potentiation of IgE synthesis, one T cell-dependent and the other T cell-independent. The clinical implications of these findings are discussed with regard to the use of CsA in the treatment of Th2-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554405      PMCID: PMC1553346          DOI: 10.1111/j.1365-2249.1995.tb06640.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation.

Authors:  D Peest; B Schaper; B Nashan; K Wonigeit; E Raude; R Pichlmayr; A Haverich; H Deicher
Journal:  Transplantation       Date:  1988-09       Impact factor: 4.939

2.  Cyclosporine in autoimmune diseases.

Authors:  J F Bach
Journal:  Transplant Proc       Date:  1989-06       Impact factor: 1.066

3.  Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations.

Authors:  L M Webster; A W Thomson
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

4.  Single step separation of human T and B cells using AET treated srbc rosettes.

Authors:  A Saxon; J Feldhaus; R A Robins
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

5.  Cyclosporin A is an adjuvant in murine IgE antibody responses.

Authors:  S S Chen; G Stanescu; A E Magalski; Y Y Qian
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

6.  Induction of graft-versus-host disease after autologous bone marrow transplantation.

Authors:  R J Jones; G B Vogelsang; A D Hess; E R Farmer; R B Mann; R B Geller; S Piantadosi; G W Santos
Journal:  Lancet       Date:  1989-04-08       Impact factor: 79.321

7.  Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs.

Authors:  A W Thomson; D K Moon; Y Inoue; C L Geczy; D S Nelson
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

8.  Inhibition of drug-induced eosinophilia by cyclosporin A.

Authors:  A W Thomson; J I Milton; R D Aldridge; R J Davidson; J G Simpson
Journal:  Scand J Immunol       Date:  1986-08       Impact factor: 3.487

9.  Cyclosporin A-induced suppression of ongoing IgE antibody formation in the mouse.

Authors:  H Okudaira; Y Sakurai; K Terada; E Terada; T Ogita; T Miyamoto
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

10.  Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution.

Authors:  A Glazier; P J Tutschka; E R Farmer; G W Santos
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.